Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Research
Brain Tumor : Recurrent ependymoma
Ependymoma is a rare type of primary brain or spinal cord tumor. Primary brain and spinal cord tumors start in the central nervous system (CNS). Occasionally, ependymoma tumor cells can spread in the cerebrospinal fluid (CSF) . Although it is very rare for ependymoma to occur in other parts of the body, the tumor cells in the CSF can cause tumors to develop in other areas of the CNS. Typically, tumor nodules form where the tumor cells settle such as at the base of the brain or bottom of the spinal cord. This type of tumor can be difficult to treat when it recurs. At this time, there is no chemotherapy treatment that has been proven to be very effective in the majority of children with recurrent disease.
This is a phase I study of a drug called 5-Fluorouracil (5-FU). This drug has been approved by the FDA and commercially available for many years. It is a drug commonly used to treat a variety of cancers (both in children and adults); however, 5-FU is not approved by the FDA to treat brain tumors in children. This drug has been used in the past for adults with brain tumors, but it was given in a different way. This is why the treatment is considered experimental (research). This study is being done to find out the best dose to give children and young adults with relapsed or recurrent ependymoma so that future studies with this drug can be done.
Karen Wright, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Phone: 901-595-2544 or 901-595-4599
FAX: 901-595-5353
Or
Tabatha E. Doyle, RN
Coordinator, Brain Tumor Program
Phone: 901-595-2544
For the current eligibility status of this clinical study, patient’s family, relatives and/or referring physicians may contact St. Jude Children’s Research Hospital at (901) 595-4599 or (901) 595-2544.
The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.
